Bcl-xL in prostate cancer cells: Effects of overexpression and down-regulation on chemosensitivity

Cancer Research

Volumn 60, Issue 21, 2000, Pages 6052-6060

  Lebedeva, I ^a   Rando, R ^a   Ojwang, J ^a   Cossum, P ^a   Stein, C A ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CARBOPLATIN; DOCETAXEL; ETOPOSIDE; MITOXANTRONE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PACLITAXEL; PROTEIN BCL 2; PROTEIN BCL X; VINBLASTINE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROTECTION; CHEMOSENSITIVITY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MEMBRANE PROTEINS; OLIGONUCLEOTIDES, ANTISENSE; PHENOTYPE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER;

EID: 0034326272     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers
2. Immunohistochemical analysis of in vivo patterns of Bcl-X expression
3. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer
4. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer
5. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo
6. Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells
7. Bcl-2 overexpression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells
8. Bcl-xL regulates the membrane potential and volume homeostasis of mitochondria
9. Overexpression of Bcl-X(L) inhibits Ara-C-induced mitochondrial loss of cytochrome c and other perturbations that activate the molecular cascade of apoptosis
10. Bcl-2 and Bcl-XL antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents
11. The release of cytochrome c from mitochondria: A primary site for Bcl-2 regulation of apoptosis
12. Prevention of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked
13. Bcl-xL regulates apoptosis by heterodimerization-dependent and -independent mechanisms
14. Cell-specific induction of apoptosis by microinjection of cytochrome c. Bcl-xL has activity independent of cytochrome c release
15. Overexpression of Bcl-2 or Bcl-xL inhibits Ara-C-induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL- 60 cells
16. 'Loop' domain is necessary for Taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting Taxol-induced cytosolic accumulation of cytochrome c and apoptosis
17. Expression of bcl-xL can confer a multidrug resistance phenotype
18. Bax-α promotes apoptosis induced by cancer chemotherapy and accelerates the activation of caspase 3-like cysteine proteases in p53 double mutant B lymphoma Namalwa cells
19. Bryostatin 1 enhances paclitaxel-induced mitochondrial dysfunction and apoptosis in human leukemia cells (U937) ectopically expressing Bcl-xL
20. Identification of immunosuppressant-induced apoptosis in a murine B- cell line and its prevention by bcl-x but not bcl-2
21. Butyrate attenuates BCLX(L) expression in human fibroblasts and acts in synergy with ionizing radiation to induce apoptosis
22. Taxol and estramustine-induced modulation of human prostate cancer cell apoptosis via alteration in bcl-xL and bak expression
23. Acceleration of apoptotic cell death after the cleavage of Bcl-xL protein by caspase-3-like proteases
24. Apoptosis and Bcl-2 expression in cultured murine splenic T cells
25. Inhibition of high affinity basic fibroblast growth factor binding by oligonucleotides
26. Minimally modified oligonucleotides-combination of end-capping and pyrimidine protection
27. Cationic porphyrins: Novel delivery vehicles for antisense oligodeoxynucleotides
28. Bcl-2 family proteins and mitochondria
29. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells
30. Inactivation of Bcl-2 by phosphorylation
31. Bcl-XL, and Bcl-2 repress a common pathway of cell death
32. Bcl-2, Bcl-XL and adenovirus protein E1B19kD are functionally equivalent in their ability to inhibit cell death
33. Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells
34. Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death
35. Distinct sites of action of Bcl-2 and Bcl-xL in the ceramide pathway of apoptosis
36. Role for Bcl-xL in delayed eosinophil apoptosis mediated by granulocyte- macrophage colony-stimulating factor and interleukin-5
37. Inhibition of Bcl-xL expression sensitizes normal human keratinocytes and epithelial cells to apoptotic stimuli
38. The role of antiapoptotic Bcl-2 family members in endothelial apoptosis elucidated with antisense oligonucleotides
39. Inhibition of protein kinase C-α expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides
40. Site and mechanism of antisense inhibition by C-5 propyne oligonucleotides
41. The development of C-5 propyne oligonucleotides as inhibitors of gene function
42. Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines
43. Exploiting the potential of antisense: Beyond phosphorothioate oligonucleotides
44. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix
45. BCL-2
46. Is irrelevant cleavage the price of antisense efficacy?
47. Determining the influence of structure on hybridization using oligonucleotide arrays
48. Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression
49. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells
50. Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms
51. Identification and partial purification of human double strand RNase activity. A novel terminating mechanism for oligoribonucleotide antisense drugs
52. Translationally associated helix-destabilizing activity in rabbit reticulocyte lysate
53. Destabilization of messenger RNA/complementary DNA duplexes by the elongating 80 S ribosome